Navigation Links
Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
Date:3/13/2008

our work with AstraZeneca in this important therapeutic area, and are extremely excited about the potential of our AtuPLEX delivery technology today and its ability to be developed further so that it can become an even more significant value driver for Silence Therapeutics."

Silence Therapeutics will retain the right to sign further 'delivery' deals to capture value from its current AtuPLEX delivery technology as well as any improvements to this technology that it generates either independently or as part of this collaboration.

Claude Bertrand, Global VP, Discovery Respiratory & Inflammation, at AstraZeneca said, "We are very happy with the working relationship we have developed with the team at Silence Therapeutics and the progress made over the last six months via our agreement to develop siRNA therapeutics against a number of our targets. Today's announcement is designed to generate the novel delivery approaches that are needed if this exciting class of novel drugs is to realize fully its potential. Based on Silence Therapeutics' significant current expertise in siRNA delivery we are confident that we have found a strong partner to achieve our ambitions in this area."

Notes to Editors

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (LSE: SLN) is a leading RNAi company. RNA interference (RNAi) can selectively 'silence' genes linked to the onset of disease.

Silence Therapeutics has developed novel, proprietary short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellu
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
2. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
3. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
4. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
5. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
6. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
7. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
8. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
9. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
10. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
11. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
(Date:8/20/2014)... American Indians largely were wiped out by diseases such ... to the New World by European explorers., One report ... in the Americas shortly before Europeans arrived, and roughly ... But new research led by anthropological geneticists Anne Stone ... University of Tubingen in Germany indicates the diagnosis of ...
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Seeing a molecule breathe 2Neurotrope To Host Conference Call 2
... season on CEOs lately but when luminaries like management god ... something real and serious is taking place. Heres what Herr ... January 12, 2004 issue of Fortune Magazine, the compensation inflation ... of the management team. In an executive program I have ...
... Wis. The recent onslaught of e-mail viruses, overabundant ... for computer user protection. In light of this, ... Wisconsin companies, recently began offering new computer security technologies ... spam cost U.S. corporations $8.9 billion dollars in 2002 ...
... DEMO 2004 reaches its final week, I promised I'd share ... not just at DEMO, but in the week ahead. , ... it feels a lot like the enterprise market some 20 ... departments in the early 80s) is acutely focused on the ...
Cached Biology Technology:The CEO Crisis 2Wisconsin Telcos Offer New Internet Security Solutions 2The Enterprise and the Individual 2The Enterprise and the Individual 3
(Date:8/20/2014)... of Tennessee, Knoxville, research finds life can persist in ... was part of a team that examined waters and ... ice sheet and found the extreme environment supports microbial ... Jill Mikucki and her colleagues has implications for life ... the solar system. The findings are published in the ...
(Date:8/20/2014)... Issue Serious allergic reactions to food often ... some children.    What you should know ... and this number may be increasing, especially among children. Up ... food allergies.  The symptoms of allergic reactions ... difficulties and loss of consciousness. Symptoms can also develop at ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... and going to work is hard enough every day. But ... of your job down the smallest detail and the ... of credentials might mean starting from scratch. These are the ... make U.S. homes more energy efficient. A recent collaboration ...
... called ADAP (adhesion and degranulation-promoting adaptor protein) is able ... new University of Cambridge research reveals. The researchers, who ... discovery will lead to new ways of combatting HIV. ... who led the research, said: "One exciting aspect about ...
... Oct. 1, 2013  Pfenex Inc. today announced that the ... Biomedical Advanced Research and Development Authority (BARDA), has modified ... with the existing Pfenex contractual relationship begun in July, ... funding to support the development of a next generation ...
Cached Biology News:Weatherization work guidelines launched 2Weatherization work guidelines launched 3Weatherization work guidelines launched 4Weatherization work guidelines launched 5Weatherization work guidelines launched 6New target to fight HIV infection identified 2Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine 2
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Mouse monoclonal antibody to PAEP - progestagen-associated endometrial protein (placental protein 14, pregnancy-associated endometrial alpha-2-globulin, alpha uterine protein)...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
Biology Products: